A Dual Role of Type I Interferons in Antitumor Immunity

Lili Zhou,Yuqi Zhang,Yongqiang Wang,Meirong Zhang,Wenhuan Sun,Tong Dai,Aijun Wang,Xiaojin Wu,Suping Zhang,Shuai Wang,Fangfang Zhou
DOI: https://doi.org/10.1002/adbi.201900237
IF: 4.0531
2020-01-01
Advanced Biosystems
Abstract:Type I interferons (IFN-Is) are a family of cytokines that exert direct antiviral effects and regulate innate and adaptive immune responses through direct and indirect mechanisms. It is generally believed that IFN-Is repress tumor development via restricting tumor proliferation and inducing antitumor immune responses. However, recent emerging evidence suggests that IFN-Is play a dual role in antitumor immunity. That is, in the early stage of tumorigenesis, IFN-Is promote the antitumor immune response by enhancing antigen presentation in antigen-presenting cells and activating CD8(+)T cells. However, in the late stage of tumor progression, persistent expression of IFN-Is induces the expression of immunosuppressive factors (PD-L1, IDO, and IL-10) on the surface of dendritic cells and other bone marrow cells and inhibits their antitumor immunity. This review outlines these dual functions of IFN-Is in antitumor immunity and elucidates the involved mechanisms, as well as their applications in tumor therapy.
What problem does this paper attempt to address?